BROOKS LAB LIMITED (BROOKS) financials

BROOKS LAB LIMITED (BROOKS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]

Market Cap: ₹199Cr.
Current Price: ₹67.6
Stock P/E: 43.6
ROE: 4.68%
ROCE: 5.04%
Book Value: ₹41.0
Dividend Yield: 0.00%
52W High / Low: ₹131/36.3

In Jun 2026, BROOKS LAB LIMITED (BROOKS) reported sales ₹22.96 Cr and net profit ₹1.42 Cr.

Annual TTM: sales ₹83.19 Cr, net profit ₹4.57 Cr.

Shareholding: Promoters 52.62% (Jun 2026), FIIs 0.00% (Jun 2026), DIIs 10.38% (Jun 2026), Public 37.00% (Jun 2026), No. of Shareholders 11,161% (Jun 2026).

BROOKS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	20.79	20.52	23.32	25.51	23.45	16.57	20.21	22.96
Expenses	19.28	18.95	21.74	22.39	20.93	15.84	19.53	21.10
Operating Profit	1.51	1.57	1.58	3.12	2.52	0.73	0.68	1.86
OPM %	7.26%	7.65%	6.78%	12.23%	10.75%	4.41%	3.36%	8.10%
Other Income	0.20	0.03	0.62	0.22	0.39	0.13	0.44	0.18
Interest	0.32	0.28	0.26	0.30	0.28	0.16	0.09	0.21
Depreciation	0.43	0.38	0.39	0.39	0.39	0.39	0.41	0.42
Profit before tax	0.96	0.94	1.55	2.65	2.24	0.31	0.62	1.41
Tax %	0.00%	0.00%	11.61%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.96	0.94	1.37	2.65	2.24	0.30	0.61	1.42
EPS in Rs	0.37	0.36	0.47	0.90	0.76	0.10	0.21	0.48
Raw PDF	—	—	—	—	—	—	—	—

BROOKS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	69.69	76.66	76.97	55.54	79.49	82.56	85.74	83.19
Expenses	72.27	75.65	75.10	61.36	76.24	77.58	78.68	77.40
Operating Profit	-2.58	1.01	1.87	-5.82	3.25	4.98	7.06	5.79
OPM %	-3.70%	1.32%	2.43%	-10.48%	4.09%	6.03%	8.23%	6.96%
Other Income	-0.94	0.90	0.95	0.12	0.92	0.88	1.17	1.14
Interest	3.35	3.25	0.67	0.77	0.84	1.03	0.84	0.74
Depreciation	6.65	7.09	1.49	1.72	1.77	1.60	1.59	1.61
Profit before tax	-13.52	-8.43	0.66	-8.19	1.56	3.23	5.80	4.58
Tax %	80.33%	84.82%	0.00%	0.00%	1.92%	5.57%	0.00%	—
Net Profit	-24.38	-15.59	0.67	-8.18	1.53	3.05	5.81	4.57
EPS in Rs	-9.31	-5.95	0.26	-3.12	0.58	1.04	1.97	1.55
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	—

BROOKS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16.19	24.70	24.70	24.70	24.70	26.25	29.46	29.46
Reserves	88.96	73.71	39.51	40.30	32.08	43.28	85.61	91.39
Borrowings	31.18	27.64	8.40	5.97	6.51	5.64	7.58	8.52
Other Liabilities	31.55	31.81	20.39	32.48	29.13	19.22	18.01	16.99
Total Liabilities	167.88	157.86	93.00	103.45	92.42	94.39	140.66	146.36
Fixed Assets	117.70	113.02	14.96	15.14	15.01	13.67	13.98	14.52
CWIP	0.29	0.11	0.02	1.12	0.00	0.00	0.00	1.19
Investments	0.02	0.02	46.81	46.84	46.85	46.86	90.52	90.53
Other Assets	49.87	44.71	31.21	40.35	30.56	33.86	36.16	40.12
Total Assets	167.88	157.86	93.00	103.45	92.42	94.39	140.66	146.36

BROOKS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-5.05	-9.39	-0.90	3.12	0.55	-9.80	2.63	9.29
Cash from Investing Activity	1.12	-2.33	-0.74	1.12	-0.40	0.18	-45.14	-2.92
Cash from Financing Activity	5.78	9.61	1.31	-4.23	-0.21	9.72	42.43	0.17
Net Cash Flow	1.85	-2.10	-0.33	0.02	-0.06	0.10	-0.08	6.54
Free Cash Flow	-4.39	-11.54	-2.07	4.26	0.08	-10.24	1.72	6.06
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	54%	364%	327%	181%	-13%	-308%	43%	131%

BROOKS shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	63.59%	59.06%	52.62%	52.62%	52.62%	52.62%	52.62%	52.62%
FIIs	0.02%	0.01%	0.05%	0.00%	0.01%	0.09%	0.17%	0.00%
DIIs	3.86%	3.86%	10.38%	10.38%	10.38%	10.38%	10.38%	10.38%
Public	32.53%	37.08%	36.95%	37.00%	37.00%	36.91%	36.84%	37.00%
No. of Shareholders	11,282	10,521	10,537	10,317	10,078	10,532	10,741	11,161

BROOKS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	75.75	81.50	45.66	71.27	83.79	74.94	88.38	68.58
Inventory Days	93.03	107.30	91.81	119.53	99.41	60.49	60.56	76.83
Days Payable	251.23	203.15	99.30	185.53	205.59	97.25	89.65	79.76
Cash Conversion Cycle	-82.45	-14.35	38.17	5.28	-22.39	38.18	59.28	65.65
Working Capital Days	-125.82	-49.28	-5.86	2.37	-42.65	33.57	43.28	34.31
ROCE %	-8.72%	-6.72%	-5.15%	1.49%	-11.07%	3.45%	4.29%	5.04%

BROOKSUpdated 18 Oct 2026, 9:27

Brooks Lab Limited

BROOKSUpdated 18 Oct 2026, 9:27

Market Cap

₹199Cr.

Current Price

₹67.6

High / Low

₹131/36.3

Stock P/E

43.6

ROE4.68%

ROCE5.04%

Book Value₹41.0

Face Value₹10.0

Dividend Yield0.00%

About

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	15.7	0.17	15.67	0.05	0.44	-0.53	0	-0.53	-0.2
Sep 2023	24.32	0.19	22.6	0.09	0.44	1.18	0	1.18	0.45
Dec 2023	21.75	0.21	20.66	0.16	0.43	0.61	4.92	0.58	0.22
Mar 2024	17.72	0.27	17.34	0.65	0.46	0.3	0	0.3	0.11
Jun 2024	17.93	0.16	17.65	0.07	0.4	-0.21	0	-0.21	-0.08
Sep 2024	20.79	0.32	19.28	0.2	0.43	0.96	0	0.96	0.37
Dec 2024	20.52	0.28	18.95	0.03	0.38	0.94	0	0.94	0.36
Mar 2025	23.32	0.26	21.74	0.62	0.39	1.55	11.61	1.37	0.47
Jun 2025	25.51	0.3	22.39	0.22	0.39	2.65	0	2.65	0.9
Sep 2025	23.45	0.28	20.93	0.39	0.39	2.24	0	2.24	0.76
Dec 2025	16.57	0.16	15.84	0.13	0.39	0.31	0	0.3	0.1
Mar 2026	20.21	0.09	19.53	0.44	0.41	0.62	0	0.61	0.21
Jun 2026	22.96	0.21	21.1	0.18	0.42	1.41	0	1.42	0.48

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	85.21	0.44	78.36	5.04	1.1	10.35	8.5	9.47	3.8
Mar 2016	80.01	0.79	68.93	1.69	1.16	10.82	1.66	10.63	4.27
Mar 2017	57.54	1.01	52.5	0.12	1.67	2.48	33.06	1.67	0.67
Mar 2018	55.71	2.4	64.64	0.24	6.45	-17.54	-21.21	-13.81	-5.55
Mar 2019	55.03	2.96	63.4	2.88	6.5	-14.95	-0.94	-14.81	-5.95
Mar 2020	69.69	3.35	72.27	-0.94	6.65	-13.52	80.33	-24.38	-9.31
Mar 2021	76.66	3.25	75.65	0.9	7.09	-8.43	84.82	-15.59	-5.95
Mar 2022	76.97	0.67	75.1	0.95	1.49	0.66	0	0.67	0.26
Mar 2023	55.54	0.77	61.36	0.12	1.72	-8.19	0	-8.18	-3.12
Mar 2024	79.49	0.84	76.24	0.92	1.77	1.56	1.92	1.53	0.58
Mar 2025	82.56	1.03	77.58	0.88	1.6	3.23	5.57	3.05	1.04
Mar 2026	85.74	0.84	78.68	1.17	1.59	5.8	0	5.81	1.97
TTM	83.19	0.74	77.4	1.14	1.61	4.58	—	4.57	1.55

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	52.62%
DIIs	10.38%
Public	37%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	63.59%	0%	2.46%	33.94%
Dec 2023	63.59%	0%	3.86%	32.56%
Mar 2024	63.59%	0%	3.86%	32.55%
Jun 2024	63.59%	0%	3.86%	32.55%
Sep 2024	63.59%	0.02%	3.86%	32.53%
Dec 2024	59.06%	0.01%	3.86%	37.08%
Mar 2025	52.62%	0.05%	10.38%	36.95%
Jun 2025	52.62%	0%	10.38%	37%
Sep 2025	52.62%	0.01%	10.38%	37%
Dec 2025	52.62%	0.09%	10.38%	36.91%
Mar 2026	52.62%	0.17%	10.38%	36.84%
Jun 2026	52.62%	0%	10.38%	37%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	16.19	95.23	0.51	23.61	135.54	15.68	52.86	0.02	66.98	135.54
Mar 2016	16.19	105.86	5.71	24.77	152.53	16.34	86.86	0.02	49.31	152.53
Mar 2017	16.19	112.09	13.72	22.13	164.13	125.95	0	0.02	38.16	164.13
Mar 2018	16.19	98.29	27.98	30.21	172.67	124.64	0.52	0.02	47.49	172.67
Mar 2019	16.19	88.96	31.18	31.55	167.88	117.7	0.29	0.02	49.87	167.88
Mar 2020	24.7	73.71	27.64	31.81	157.86	113.02	0.11	0.02	44.71	157.86
Mar 2021	24.7	39.51	8.4	20.39	93	14.96	0.02	46.81	31.21	93
Mar 2022	24.7	40.3	5.97	32.48	103.45	15.14	1.12	46.84	40.35	103.45
Mar 2023	24.7	32.08	6.51	29.13	92.42	15.01	0	46.85	30.56	92.42
Mar 2024	26.25	43.28	5.64	19.22	94.39	13.67	0	46.86	33.86	94.39
Mar 2025	29.46	85.61	7.58	18.01	140.66	13.98	0	90.52	36.16	140.66
Mar 2026	29.46	91.39	8.52	16.99	146.36	14.52	1.19	90.53	40.12	146.36

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	2.13	-1.12	-0.07	0.94
Mar 2016	8.12	-13.56	4.32	-1.12
Mar 2017	9.56	-16.8	7.01	-0.23
Mar 2018	-6.18	-5.14	11.82	0.51
Mar 2019	-5.05	1.12	5.78	1.85
Mar 2020	-9.39	-2.33	9.61	-2.1
Mar 2021	-0.9	-0.74	1.31	-0.33
Mar 2022	3.12	1.12	-4.23	0.02
Mar 2023	0.55	-0.4	-0.21	-0.06
Mar 2024	-9.8	0.18	9.72	0.1
Mar 2025	2.63	-45.14	42.43	-0.08
Mar 2026	9.29	-2.92	0.17	6.54

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	82.63	86.27	67.81	66.70	75.75	81.50	45.66	71.27	83.79	74.94	88.38	68.58
Inventory Days	45.32	46.12	75.53	103.93	93.03	107.30	91.81	119.53	99.41	60.49	60.56	76.83
Days Payable	114.65	108.29	180.19	242.76	251.23	203.15	99.30	185.53	205.59	97.25	89.65	79.76
Cash Conversion Cycle	13.30	24.09	-36.85	-72.12	-82.45	-14.35	38.17	5.28	-22.39	38.18	59.28	65.65
Working Capital Days	41.64	-0.96	-26.83	-76.92	-125.82	-49.28	-5.86	2.37	-42.65	33.57	43.28	34.31
ROCE %	7.24%	9.58%	2.59%	-10.64%	-8.72%	-6.72%	-5.15%	1.49%	-11.07%	3.45%	4.29%	5.04%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of BROOKS LAB LIMITED (BROOKS)?

The reported market capitalisation for BROOKS LAB LIMITED (BROOKS) is ₹199Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of BROOKS?

The current price shown for BROOKS LAB LIMITED (BROOKS) on Fincrux is ₹67.6 with a 52-week high/low of ₹131/36.3.

What is the P/E ratio of BROOKS LAB LIMITED (BROOKS)?

The stock P/E for BROOKS LAB LIMITED (BROOKS) is 43.6 on Fincrux, with ROE at 4.68% and ROCE at 5.04%.

What were BROOKS latest quarterly results?

For Jun 2026, BROOKS LAB LIMITED (BROOKS) reported sales ₹22.96 Cr and net profit ₹1.42 Cr (figures in ₹ crore unless noted).

What are BROOKS annual sales and net profit?

For TTM, BROOKS LAB LIMITED (BROOKS) shows sales of ₹83.19 Cr and net profit of ₹4.57 Cr on the Fincrux profit & loss statement.

Who owns BROOKS LAB LIMITED (BROOKS)?

Latest shareholding for BROOKS LAB LIMITED (BROOKS) on Fincrux: Promoters 52.62% (Jun 2026), FIIs 0.00% (Jun 2026), DIIs 10.38% (Jun 2026), Public 37.00% (Jun 2026), No. of Shareholders 11,161% (Jun 2026).

Where can I find BROOKS LAB LIMITED (BROOKS) financials?

BROOKS LAB LIMITED (BROOKS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show BROOKS balance sheet and cash flow?

Yes. The BROOKS LAB LIMITED (BROOKS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 9:27